# US 2024/0002941 A1 · Method for predicting patient response to cd40-targeted therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002941 A1
- Document ID: US20240002941A1
- Status: Published application
- Kind: A1
- Application number: 18/254,242
- Filed: 2021-12-02
- Published: 2024-01-04
- Earliest claimed: 2020-12-02
- Assignees: Albert Einstein College of Medicine; Montefiore Medical Center; Johannes Gutenberg University (JGU) Medical Center
- Applicants: Albert Einstein College of Medicine; Montefiore Medical Center; Johannes Gutenberg University (JGU) Medical Center
- Inventors: Yaron Tomer; Larissa C. Faustino; George J. Kahaly
- Web page: https://patentgrep.com/patent/US20240002941A1

## CPC

- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- C07K 2317/21: from primates, e.g. man
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/70578: NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
- G01N 2800/24: Immunology or allergic disorders
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Methods of predicting response of a subject in need of immunosuppressant therapy to a Cluster of differentiation 40 (CD40)-targeted treatment are disclosed. The methods permit treating the subject with a treatment most likely to show a favorable response.

## Claims

### Claim 1

A method for predicting response of a subject to a Cluster of differentiation 40 (CD40)-targeted treatment, comprising
genotyping Cluster of differentiation 40 (CD40) single nucleotide polymorphism (SNP) rs1883832 and/or rs4810485 in a biological sample from a subject in need of immunosuppressant therapy; and
predicting that the subject will respond to treatment with a CD40-targeted active agent when the determined genotype of rs1883832 is homozygous for C or when the determined genotype of rs4810485 is homozygous for G, or
predicting that the subject will not respond to treatment with a CD40-targeted active agent when the determined genotype of rs1883832 is heterozygous or homozygous for T or when the determined genotype of rs4810485 is heterozygous or homozygous for T.

### Claim 2 (depends on 1)

The method of claim 1, further comprising
administering a CD40-targeted active agent to the subject when the determined genotype of rs1883832 is homozygous for C or when the determined genotype of rs4810485 is homozygous for G; or
administering a treatment to the subject that does not target CD40 when the determined genotype of rs1883832 is heterozygous or homozygous for T or when the determined genotype of rs4810485 is heterozygous or homozygous for T.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject in need of immunosuppressant therapy is a patient with an autoimmune disease, a candidate for a transplant, or a recipient of a transplant.

### Claim 4 (depends on 1)

The method of claim 1, wherein the subject in need of immunosuppressant therapy is a patient with an autoimmune disease and wherein the autoimmune disease is Graves' disease, antibody mediated autoimmune thyroid disease, Rheumatoid arthritis, Multiple Sclerosis (MS), Myasthenia Gravis, Sjogren's syndrome, Systemic Lupus Erythematosus, Crohn's disease, or a combination thereof.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject in need of immunosuppressant therapy is a candidate for a transplant or a recipient of a transplant, and wherein the transplant is of a tissue or an organ.

### Claim 6 (depends on 1)

The method of claim 1, further comprising
genotyping rs6074022, rs745307, rs11569309, rs3765457, rs112809897, a SNP within 1 million base pairs distance upstream or downstream from rs1883832 in strong linkage disequilibrium with rs1883832, wherein strong linkage disequilibrium is defined as coefficient of correlation (r) square (r2) value ≥0.7, or a combination thereof in the biological sample;
determining a haplotype pair from the genotypes; and
predicting that the subject will respond to treatment with a CD40-targeted active agent when the determined haplotype pair comprises a rs1883832 genotype homozygous for C or a rs4810485 homozygous for G, or
predicting that the subject will not respond to treatment with a CD40-targeted active agent when the determined haplotype comprises a rs1883832 genotype heterozygous or homozygous for T or a rs4810485 genotype heterozygous or homozygous for T.

### Claim 7 (depends on 1)

The method of claim 1, wherein the CD40-targeted active agent is an antagonistic anti-CD40 antibody.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antagonistic anti-CD40 antibody is BI 655064, ch5D12, bleselumab (ASKP 1240), Abbv-323 (ravagalimab), or iscalimab (CFZ533).

### Claim 9 (depends on 1)

The method of claim 1, wherein the treatment that does not target CD40 is administration of one or more active agents in which the mode of action does not directly target CD40, surgery, and/or a behavioral or diet therapy.

### Claim 10 (depends on 1)

The method of claim 1, further comprising obtaining the biological sample from the subject.

### Claim 11

(canceled)

### Claim 12

A method for predicting response of a subject to a Cluster of differentiation (CD40)-targeted treatment, comprising
determining Cluster of differentiation 40 (CD40) expression levels in a biological sample from a subject in need of immunosuppressant therapy; and
predicting that the subject will respond to treatment with a CD40-targeted active agent when the determined CD40 expression level is greater than 0.3% of GAPDH expression level in the biological sample, or
predicting that the subject is unlikely to respond to treatment with a CD40-targeted active agent when the determined CD40 expression level is below 0.3% of GAPDH expression level in the biological sample.

### Claim 13 (depends on 12)

The method of claim 12, further comprising
administering a CD40-targeted active agent to the subject when the determined CD40 expression level is greater than or equal to 0.3% of GAPDH expression level in the biological sample; or
administering a treatment that does not target CD40 to the subject when the determined CD40 expression level is below 0.3% of GAPDH expression level in the biological sample.

### Claim 14 (depends on 12)

The method of claim 12, wherein the subject in need of immunosuppressant therapy is a patient with an autoimmune disease, a candidate for a transplant, or a recipient of a transplant.

### Claim 15 (depends on 12)

The method of claim 12, wherein the subject in need of immunosuppressant therapy is a patient with an autoimmune disease and wherein the autoimmune disease is Graves' disease, antibody mediated autoimmune thyroid disease, Rheumatoid arthritis, Multiple Sclerosis (MS), Myasthenia Gravis, Sjogren's syndrome, Systemic Lupus Erythematosus, Crohn's disease, or a combination thereof; preferably the autoimmune disease is Graves' disease.

### Claim 16 (depends on 12)

The method of claim 12, wherein the subject in need of immunosuppressant therapy is a candidate for a transplant or a recipient of a transplant, and wherein the transplant is of a tissue or an organ, preferably the transplant is of an organ and the organ is a kidney, a liver, a heart, or a lung.

### Claim 17 (depends on 12)

The method of claim 12, wherein the CD40-targeted active agent is an antagonistic anti-CD40 antibody, preferably the anti CD40 antibody is a fully human or a humanized antibody.

### Claim 18 (depends on 17)

The method of claim 17, wherein the antagonistic anti-CD40 antibody is BI 655064, ch5D12, bleselumab (ASKP 1240), Abbv-323 (ravagalimab), or iscalimab (CFZ533).

### Claim 19 (depends on 12)

The method of claim 12, wherein the treatment that does not target CD40 is administration of one or more active agents in which the mode of action does not directly target CD40, surgery, and/or a diet or behavioral therapy.

### Claim 20 (depends on 12)

The method of claim 12, further comprising obtaining the biological sample from the subject.

### Claim 21

(canceled)

### Claim 22 (depends on 12)

The method of claim 12, wherein expression levels are mRNA expression levels or protein expression levels.

### Claim 23

(canceled)
